Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel small and large molecule therapies for immuno-inflammatory diseases. Utilizing its proprietary KINect drug discovery platform, Aclaris advances biologics and kinase inhibitor candidates targeting validated pathways. Its pipeline includes monoclonal and bispecific antibodies, oral kinase inhibitors, and topical treatments. The company serves patients with unmet medical needs through research, development, and strategic partnerships, relying on third-party manufacturing and regulatory approvals.
This description was generated via AI from an annual report. Updated about 1 year ago.